MRK

Moderna's stock fell 18% after reports of a data leak regarding its personalized melanoma vaccine showed a 42% reduction in recurrence or death risk when paired with Merck's Keytruda—lower than Phase II results of 49%. The full Phase 3 results were scheduled for release on October 24, and the leaked figures fell short of market expectations despite the company's 600% gain in 2026.

Summit Therapeutics announced a phase II/III clinical trial (EA2251) evaluating its investigational drug ivonescimab plus chemotherapy as a first-line treatment for advanced biliary tract cancer. The study will compare ivonescimab against Merck's Keytruda and AstraZeneca's Imfinzi, both combined with chemotherapy.

This follows positive results from the HARMONi-GI1 study, which showed ivonescimab demonstrated significant survival benefits over Imfinzi in BTC patients. Summit is expanding ivonescimab development across multiple cancer types while prioritizing lung cancer for near-term U.S. commercialization.

Merck is expected to report Q3 2026 earnings on October 29 with consensus estimates of $2.12 EPS (down 17.8% YoY) and $17.23B in revenues (down 0.3% YoY). With a negative Earnings ESP of -0.99% and a Zacks Rank #5 (Strong Sell), the stock appears unlikely to beat earnings expectations. However, Merck has beaten consensus estimates in all four of the last quarters.

Moderna has surged over 600% in 2026, driven by breakthrough Phase 3 trial results for its personalized cancer vaccine (intismeran autogene) combined with Merck's Keytruda, plus FDA approval for its flu vaccine mFLUSIVA. However, despite strong innovation, the stock appears overvalued at a $90 billion market cap with a 45% downside according to Wall Street analysts. The company would need to generate unrealistic revenue levels to justify current valuations, leaving little room for error.

Moderna is transitioning from a COVID-19 vaccine company to an oncology-focused biotech firm. The company announced positive phase 3 results for its personalized cancer vaccine (intismeran autogene) paired with Merck's Keytruda for melanoma treatment. With the global oncology market projected to grow from $253 billion to over $700 billion by 2034, Moderna's stock has surged over 600% this year, though it now trades 61% above Wall Street's average price target of $123.

Merck (MRK) closed at $143.63, down 1.59% from the previous session, underperforming the S&P 500's 0.41% gain. The pharmaceutical company faces declining earnings expectations with Q3 EPS projected at $2.12 (down 17.83% YoY) and annual EPS forecast at $2.66 (down 70.38% YoY).

With a Zacks Rank of #4 (Sell), a Forward P/E of 54.92 significantly above the industry average of 16.91, and a PEG ratio of 6.74 versus the industry average of 2.01, Merck appears overvalued. Consensus EPS estimates have fallen 3.83% over the past month.

Merck (MRK) is trending but faces headwinds with a Zacks Rank #4 (Sell) rating. The company shows significant earnings estimate revisions downward, with current fiscal year earnings expected to decline 70.4% year-over-year, though next fiscal year projects a 248.6% recovery.

Revenue growth remains modest at 3.2% for the current fiscal year. The stock has underperformed relative to the S&P 500 over the past month and is trading at par valuation with peers.

Merck's blockbuster cancer drug Keytruda generated $16.40 billion in first-half 2026 sales, up 4.2% year-over-year, with expectations for continued growth through 2028 when it reaches peak sales of $35 billion. However, the company faces significant headwinds as biosimilar competition is expected around 2028-2029, which will likely cause sharp sales declines. Merck stock has outperformed the industry year-to-date but currently holds a Zacks Rank #4 (Sell) rating.

Merck (MRK) closed down 2.39% and underperformed the S&P 500. The pharmaceutical company faces declining earnings projections with consensus estimates showing a 17.83% year-over-year EPS decline for the upcoming quarter and a 70.38% decline for the full fiscal year. The stock carries a Zacks Rank of #4 (Sell) with a Forward P/E ratio of 54.73, significantly above the industry average of 16.15.

Tempus AI (TEM) is strengthening its precision medicine presence through multiple strategic collaborations, including support for Moderna and Merck's cancer therapy commercialization and an extended data partnership with Recursion Pharmaceuticals through 2029. However, TEM's stock has underperformed the industry by 30.6% over the past year and trades at a premium valuation of 6.73X forward P/S versus the industry average of 4.90X, with the stock currently rated a Hold.

A Dutch patent court ruled that Merck's Keytruda subcutaneous formulation infringes Halozyme's MDASE patent, ordering Merck to cease manufacturing and sales across eight European markets. The ruling does not affect Keytruda's intravenous version. This marks another legal victory for Halozyme against Merck, though the company clarified that its separate ENHANZE technology and licensing business remain unaffected.

In a comparison of two large cap pharmaceutical stocks, Innoviva (INVA) emerges as the superior value option compared to Merck (MRK). INVA holds a Zacks Rank of #2 (Buy) versus MRK's #3 (Hold), and demonstrates significantly better valuation metrics including a forward P/E of 9.12 versus MRK's 53.42, a PEG ratio of 3.04 versus 6.42, and a P/B ratio of 1.24 versus 8.4. INVA received a Value grade of A while MRK received a C.

Moderna (MRNA) will be added to the Nasdaq-100 Index on October 9, replacing Warner Bros. Discovery following its acquisition by Paramount. The inclusion comes after Moderna's 566% year-to-date stock surge and positive phase III results for its personalized cancer therapy developed with Merck. While the index addition could drive incremental institutional demand through index-tracking funds managing over $800 billion in assets, it does not change the company's underlying fundamentals.

Eli Lilly's oncology segment is projected to generate $2.65 billion in Q3 2026 revenues, with growth driven by newer drugs like Jaypirca, Retevmo, and Inluriyo offsetting slower Verzenio sales. The company faces intense competition from AstraZeneca, Merck, and Pfizer in the oncology space. LLY stock has risen 10.6% year-to-date but trades at a premium valuation of 26.80x forward earnings.

Merck (MRK) closed at $141.94, up 1.72%, outperforming the S&P 500's 0.58% gain. The pharmaceutical company is set to report earnings on October 29, 2026, with forecasted EPS of $2.25 (down 12.79% YoY) and revenue of $17.52 billion (up 1.39% YoY). MRK holds a Zacks Rank #3 (Hold) with a Forward P/E of 50.47, significantly above the industry average of 15.89.

Merck's stock declined 7.2% recently after a strong 60% annual gain, but analysts view this as a healthy pullback. While the company faces near-term headwinds including Gardasil weakness, generic competition, and Keytruda's 2028 patent expiration, its expanding pipeline with 20 new drug launches expected by 2030 and strategic acquisitions position it for long-term growth. The company maintains a Hold rating with potential as a buying opportunity for long-term investors.

The VanEck Pharmaceutical ETF (PPH) offers low-cost exposure to the healthcare-pharma sector with a 0.36% expense ratio and $1.01 billion in assets. The fund tracks the MVIS US Listed Pharmaceutical 25 Index and holds major pharmaceutical companies like Eli Lilly, Merck, and Novartis. With a Zacks ETF Rank of 3 (Hold), year-to-date gains of 6.51%, and a medium-risk profile, PPH is presented as a reasonable option for investors seeking diversified pharma exposure, though alternative ETFs like FTXH and IHE are also available.

Merck announced that its investigational drug tulisokibart met the primary endpoint in a phase IIb study for moderate to severe hidradenitis suppurativa. High-dose and medium-dose regimens demonstrated superiority over placebo, with 72% and 64% of patients achieving HiSCR50 response respectively, compared to 35% for placebo.

The drug also showed improvements in quality of life measures. Merck plans to advance tulisokibart into phase III development for HS and is evaluating it across six immune-mediated indications.

Merck (MRK) declined 2.66% to $145.31, underperforming the S&P 500. The pharmaceutical company's upcoming Q3 2026 earnings are expected on October 29, with projected EPS of $2.25 (down 12.79% YoY) and revenue of $17.52 billion (up 1.39% YoY). The stock carries a Zacks Rank #3 (Hold) with a Forward P/E of 53.99, significantly above the industry average of 16.43.